Pfizer Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Albert Bourla
- Full Time Employees
- 81,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 66 Hudson Boulevard East New York City NY United States of America 10001-2192
- IPO Date
- Jun 1, 1972
- CIK
- 0000078003
- Website
- pfizer.com
- Similar Companies
- Business
- Pfizer Inc. (NYSE: PFE) develops, manufactures, and markets biopharmaceutical products worldwide, focusing on oncology, vaccines, internal medicine, inflammation and immunology, and rare diseases. The company offers a broad portfolio including oncology drugs such as Ibrance (palbociclib), Xtandi (enzalutamide), Padcev (enfortumab vedotin), Elrexfio (elranatamab), Bosulif (bosutinib), Braftovi (encorafenib), Lorbrena (lorlatinib), Talzenna (talazoparib), and Tivdak (tisotumab vedotin); vaccines like Comirnaty (COVID-19 mRNA vaccine), Prevnar 13/20 (pneumococcal conjugate vaccines), Abrysvo (RSV vaccine), and Penbraya (meningococcal vaccine); cardiovascular and metabolic treatments including Eliquis (apixaban), Vyndaqel/Vyndamax (tafamidis), and Norvasc (amlodipine); primary care products such as Zavzpret (zavegepant), Chantix (varenicline), and Litfulo (ritlecitinib); antivirals like Paxlovid (nirmatrelvir/ritonavir); and consumer brands including Advil, ChapStick, and Robitussin. Founded in 1849 by Charles Pfizer and Charles F. Erhart and headquartered at 235 East 42nd Street in Manhattan, New York City, Pfizer operates manufacturing and research facilities globally across North America, Europe, Asia, and Latin America, serving healthcare providers, governments, and patients in over 100 countries. In recent developments, Pfizer completed the acquisition of Metsera in November 2025 for an initial enterprise value of $4.9 billion plus a contingent value right, adding clinical-stage obesity and cardiometabolic candidates including oral and injectable incretins; new products and acquired launches contributed $7.3 billion in incremental revenue through Q3 2025; and the company plans $10-15 billion in business development investments for 2025, emphasizing early-stage assets and collaborations, particularly with Chinese biotechs via its Ignite platform.
Buy In July: 8 IDEAL 'Safer' S&P 500 DiviDogs
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?
Pfizer's CEO Says His Company Has a "Very Big Balance Sheet" to Do Deals. Here's the Perfect Next Acquisition Target for the Pharma Giant
$500 a Month in These Stocks Will Generate $6,700 in Passive Annual Income
Pfizer vs Verizon Communications: Which High-Yielding Dividend Stock Is the Better Buy?
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors
3 Dirt-Cheap Stocks Under $45 Built to Outperform in a Volatile Market
Wall Street Walked Away From This Powerhouse Stock, But I Am Buying It on Repeat
This 7% Yielding Healthcare Powerhouse Belongs in Retirees' Portfolios
Why Pfizer Could Prove to Be an Underrated GLP-1 Stock
Merck, AbbVie probed by US lawmakers over China clinical trials: report
Value stocks beat growth when inflation is high. Here are 13 stocks top newsletters are betting on now.
3 No-Brainer Dividend Stocks to Buy Right Now
66 With $1.3 Million. Here Are 3 Hidden Gems to Target
3 Monster Stocks to Buy Right Now With Dividend Yields of 5% or More
Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review
A CFO Departure. A Clinical Miss.
Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now
Here's How Many Shares of Pfizer You Must Own to Get $5,000 in Yearly Dividends